Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Another Delay For MannKind's Inhaled Insulin As FDA Issues 'Complete Response' Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

Biotech's share price slides as most analysts question viability going forward of Afrezza program.

You may also be interested in...



New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability

Pulmonary function data don't resolve questions about safety, analysts argue.

New MannKind Data Appear Positive, But Doubts Persist About Afrezza's Viability

Pulmonary function data don't resolve questions about safety, analysts argue.

FDA Delays Approval For MannKind's Inhaled Insulin Afrezza, Stoking Confusion

Agency will miss the Jan. 16 action date for the NDA due to a manufacturing inspection; but how the potential length of the delay remains to be seen.

Topics

UsernamePublicRestriction

Register

PS070343

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel